Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.79 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.70 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.70 |
| ▸ | BMX | P51813 | 2/20 | 0.70 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.70 |
| ▸ | IKBKB | O14920 | 1/20 | 0.70 |
| ▸ | CHUK | O15111 | 1/20 | 0.70 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
| ▸ | RAF1 | P04049 | 1/20 | 0.70 |
| ▸ | FYN | P06241 | 1/20 | 0.70 |
| ▸ | YES1 | P07947 | 1/20 | 0.70 |
| ▸ | BCR | P11274 | 1/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.70 |
| ▸ | BRAF | P15056 | 1/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.70 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.70 |
| ▸ | AXL | P30530 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21614418 | 0.95 | SRC (0.79) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL16254818 | 0.90 | SRC (0.69) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL21614430 | 0.88 | SRC (0.80) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL21614423 | 0.86 | SRC (0.81) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL26930178 | 0.86 | SRC (0.69) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL21614427 | 0.85 | SRC (0.76) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL21614415 | 0.84 | SRC (0.77) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL30986314 | 0.84 | SRC (0.77) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL17935960 | 0.83 | SRC (1.00) | SRCNTRK1EPHA2BMXEPHB4 | |
| SCHEMBL17935959 | 0.82 | SRC (1.00) | SRCNTRK1EPHA2BMXEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | claimed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | claimed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | claimed |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20210284646-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-09-16 | — | — | US | disclosed |
| EP-3795571-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-03-24 | — | — | EP | disclosed |
| WO-2020007234-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2020-01-09 | — | — | WO | disclosed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| WO-2014184069-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284646-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | ALK, BRAF, DSTYK | SRC 5/4885NTRK1 156/4885EPHA2 3604/4885 |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | SRC 222/4885NTRK1 802/4885EPHA2 1160/4885 |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | ALK, BRAF, DSTYK | SRC 5/4885NTRK1 156/4885EPHA2 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.